Evalve Granted Approval for Its MitraClip System
Evalve has received CE Mark approval for its MitraClip system, the first commercially available device which enables a non-surgical option for patients suffering from the effects of mitral regurgitation.
CE Mark approval gives Evalve the ability to train and educate physicians in Europe on the use of the MitraClip device increasing the number of patients who will potentially benefit from this innovative treatment. Evalve will work with hospitals across Europe to establish training programs which will allow physicians to gain access to this new technology.
Ferolyn Powell, president and CEO of Evalve, said: “We believe the MitraClip system has the potential to benefit patients who currently suffer from the serious effects of mitral regurgitation.”